DOI: https://doi.org/10.26641/2307-0404.2015.4.56137

Modern possibilities of antisecretory therapy in children.

T. V. Yaroshevskaya, N. B. Sapa, N. N. Kramarenko, S. P. Degtyar

Abstract


The article deals with the problem of antisecretory therapy in children with erosive gastric and duodenal lesions usingproton pump inhibitors. Taking into account low potential of side effects and drug interactions, pantoprazole was used for antisecretory therapy. Administration of preparation in two doses, one of which is in the form of intravenous infusion, from the first day of patients’ hospital stay led to the rapid relief or significant reduction of pain. In 86% of patients pain was completely controlled by day 7 of hospital stay. More than 90% of patients during therapy showed improvement of appetite and general well-being, reduction of dyspeptic symptoms (nausea, vomiting, belching). The proposed scheme of pantoprazole administration showed high efficacy and safety in chronic erosive gastroduodenitis therapy in children with severe pain.


Keywords


children; chronic gastroduodenitis; antisecretory therapy; pantoprazole

Full Text:

PDF

References


Belousov YuV. [Pediatric Gastroenterology. Clinical lectures]. Kharkov: Fact. 2007;376. Russian. 2. Demidova AL. [Retrospective analysis of treat¬ment efficiency in patients with peptic duodenal ulcer]. Gastroenterology. 2015;1(55):7-10. Ukrainian. 3. Privorotsky VF. [Acid-related diseases in chil¬dren]. SPb.:SPb-MAPO; 2009;83. Russian. 4. Sokolnik SV. [Duodenal ulcer in children: diag¬nosis, clinical features, treatment]. Chernivtsi: Medu¬nіversitet. 2013;284. Ukrainian. 5. Shadrin OG, Gerasimyuk SI. [Peptic ulcer disease in the practice of pediatric gastroenterologist]. Suchasna gastroenterologіya. 2009;4(48):76-82. Russian. 6. Shcherbakov PL, Mikheev OM, Vasnev OS. [The use of injection form of acidity inhibitor drugs in Pediatric Gastroenterology]. Lechashchiy vrach. 2008;6:27-30. Russian. 7. Kawabata H, Habu Y, Tomioka H. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 2003;17:259-64 8. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011;8:79-88. 9. Sachs G, Shin JM. The gastric H-K-ATPase as a drug target past, present and future. Clin. Gastro¬en¬terology. 2007;34:226-42. 10. Tack J, Talley NJ. Gastroduodenal disorders. Amer. J. Gastroenterol. 2010;105:757-63.


GOST Style Citations


1. Белоусов Ю.В. Педиатрическая гастроэнтеро¬логия. Клинические лекции / Ю.В. Белоусов. – Харь¬ков: Факт, 2007. – 376 с. 2. Демидова А.Л. Ретроспективний аналіз ефек¬тив¬ності лікування хворих на пептичну виразку два¬надцятипалої кишки / А.Л. Демидова // Гастроенте¬рологія. – 2015. - №1 (55). – С. 7-10. 3. Приворотский В.Ф. Кислотозависимые заболе¬ва¬ния у детей / В.Ф. Приворотский, Н.Е. Луппова. - СПб.: СПб–МАПО, 2005. – 83с. 4. Сокольник С.В. Виразкова хвороба дванад¬цяти¬палої кишки в дітей: діагностика, клініка, ліку¬вання / С.В. Сокольник. - Чернівці: Медуніверситет, 2013.-284 с. 5. Шадрин О.Г. Язвенная болезнь в практике дет¬ского гастроэнтеролога / О.Г. Шадрин, С.И. Гера¬си¬мюк // Сучасна гастроентерологія. – 2009. – № 4 (48). – С. 76 - 82 6. Щербаков П.Л. Использование инъекционных форм кислотоподавляющих препаратов в детской гастроэнтерологии / П.Л. Щербаков, О.М. Михеева, О.С. Васнев // Лечащий врач. – 2008. – № 6. – С. 27 – 30 7. Kawabata H. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and anti¬biotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin / H. Kawabata, Y. Habu, H. Tomioka // Aliment. Pharmacol. Ther. – 2003. – Vol. 17. – P. 259 - 264. 8. Rimbara E. Optimal therapy for Helicobacter py¬lori infections. E. Rimbara, L.A. Fischbach, D.Y. Graham // Nat. Rev. Gastroenterol. Hepatol. – 2011. – Vol. 8. – P. 79 - 88. 9. Sachs G. The gastric H-K-ATPase as a drug tar¬get past, present and future / G. Sachs, J.M. Shin // Clin. Gastroenterology. - 2007. – Vol. 34. – P. 226-242. 10. Tack J. Gastroduodenal disorders / J. Tack, NJ. Talley // Amer. J. Gastroenterol. – 2010. – Vol. 105. – P. 757-763.




 

This work is licensed under a Creative Commons Attribution 4.0 International License